ADC Therapeutics Set to Showcase Innovations at Notable Investor Conferences
Upcoming Investor Conferences
ADC Therapeutics, a leader in the field of antibody-drug conjugates (ADCs), is set to participate in two crucial investor conferences this May and June. These events signify an important platform for the company as it seeks to showcase its innovative advancements in cancer treatment through its proprietary ADC technology.
RBC Capital Markets Global Healthcare Conference
- - Date: May 21, 2025
- - Time: 10:30 AM - 10:55 AM ET
- - Format: Fireside Chat
- - Speaker: Ameet Mallik, Chief Executive Officer
This event marks an essential opportunity for ADC Therapeutics to engage with investors, highlighting their strategic initiatives and the progress they have made in developing effective therapies for hematologic malignancies. Investors and stakeholders will gain insights into the company’s future clinical projects and its ongoing commitment to transforming the cancer treatment landscape.
Jefferies Global Healthcare Conference
- - Date: June 5, 2025
- - Time: 9:55 AM - 10:25 AM ET
- - Format: Fireside Chat
- - Speaker: Ameet Mallik, Chief Executive Officer
The Jefferies conference will further delve into ADC Therapeutics’ pioneering efforts in the ADC domain. Attendees will learn about the latest advancements and partnerships that have the potential to enhance the treatment paradigm for patients with challenging conditions such as lymphoma and solid tumors.
Live Webcasts and Accessibility
Both sessions will be available for live viewing on the ADC Therapeutics Investors website. Following the live presentations, each webcast will be accessible for approximately 30 days, allowing those who cannot attend in real time to catch up on the discussions and insights presented.
About ADC Therapeutics
ADC Therapeutics is redefining the landscape of cancer treatment through its innovative ADC technology. Based in Lausanne, Switzerland, and with operations in London and New Jersey, the company is focused on advancing its platform to provide targeted therapies for patients with hematologic and solid tumors.
The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has achieved accelerated approval by the FDA, specifically targeting relapsed or refractory diffuse large B-cell lymphoma. This important milestone reflects the company’s dedication to improving patient outcomes through cutting-edge biopharmaceuticals.
In addition to ZYNLONTA, ADC Therapeutics is actively developing several other ADC candidates, engaging in both clinical and preclinical projects aimed at expanding its therapeutic portfolio. The company's growth reflects an ongoing commitment to innovation and a patient-centric approach in drug development.
Conclusion
The participation of ADC Therapeutics in these notable investor conferences serves as a prime opportunity for investors to gather crucial insights into the company’s future trajectory and ongoing clinical innovations. As ADC Therapeutics continues to lead the charge in the ADC space, the medical and investment communities alike remain keenly interested in its advancements and their potential impact on cancer care.
For further details, please visit the ADC Therapeutics website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.